Development of a humanised antibody for treatment of cancer and stroke

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1038334

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The protein PDGF-CC has a critical role in blood vessel development, and is implicated in the development of cancer, and the debilitating consequences of acute stroke. Researchers in the Ludwig Institute for Cancer Research have developed novel anti-PDGF-CC antibodies. The research program proposed will generate data and clinical reagents that will enable a lead candidate anti-PDGF-CC antibody to be commercialised, and ultimately evaluated clinically in cancer and stroke patients.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2013

Funding Scheme: NHMRC Development Grants

Funding Amount: $400,142.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

animal model | antibody cancer therapy | antibody engineering | immunohistochemistry | stroke

Related Links